Spruce

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB

Retrieved on: 
Monday, April 8, 2024
Congenital adrenal hyperplasia, Prior, News, LLP, Spruce, CAH, Hyperandrogenism, Pomerantz

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc.  (“Spruce” or the “Company”) (NASDAQ: SPRB).

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc.  (“Spruce” or the “Company”) (NASDAQ: SPRB).
  • The investigation concerns whether Spruce and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB

Retrieved on: 
Sunday, March 31, 2024
Congenital adrenal hyperplasia, Prior, News, LLP, Spruce, CAH, Hyperandrogenism, Pomerantz

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc.  (“Spruce” or the “Company”) (NASDAQ: SPRB).

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc.  (“Spruce” or the “Company”) (NASDAQ: SPRB).
  • The investigation concerns whether Spruce and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Attention Spruce Biosciences Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Tuesday, March 26, 2024
Spruce, The Company

​LOS ANGELES, March 26, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spruce Biosciences, Inc. ("Spruce" or the "Company") (NASDAQ: SPRB) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Spruce stock. Spruce investors are encouraged to contact the firm to discuss their legal rights.

Key Points: 
  • ​LOS ANGELES, March 26, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spruce Biosciences, Inc. ("Spruce" or the "Company") (NASDAQ: SPRB) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Spruce stock.
  • Spruce investors are encouraged to contact the firm to discuss their legal rights.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB

Retrieved on: 
Saturday, March 23, 2024
Congenital adrenal hyperplasia, News, LLP, Spruce, CAH, Hyperandrogenism, Pomerantz

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc. (“Spruce” or the “Company”) (NASDAQ: SPRB).

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc. (“Spruce” or the “Company”) (NASDAQ: SPRB).
  • The investigation concerns whether Spruce and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB

Retrieved on: 
Friday, March 15, 2024
Congenital adrenal hyperplasia, Prior, News, LLP, Spruce, CAH, Hyperandrogenism, Pomerantz

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc.  (“Spruce” or the “Company”) (NASDAQ: SPRB).

Key Points: 
  • NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc.  (“Spruce” or the “Company”) (NASDAQ: SPRB).
  • The investigation concerns whether Spruce and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Retrieved on: 
Thursday, March 21, 2024
Class Action Lawsuit, Professional Services, Legal, Workforce, Spruce, Alpha, CAH, News

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spruce Biosciences, Inc. (“Spruce” or “the Company”) (NASDAQ: SPRB).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spruce Biosciences, Inc. (“Spruce” or “the Company”) (NASDAQ: SPRB).
  • Investors who purchased Spruce securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SPRB .
  • You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Retrieved on: 
Thursday, March 14, 2024
Class Action Lawsuit, Professional Services, Legal, Workforce, Spruce, Alpha, CAH, News

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spruce Biosciences, Inc. (“Spruce” or “the Company”) (NASDAQ: SPRB).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spruce Biosciences, Inc. (“Spruce” or “the Company”) (NASDAQ: SPRB).
  • Investors who purchased Spruce securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SPRB .
  • You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Pharmaceutical, Health, Research, A4, GC, Congenital adrenal hyperplasia, Administration, PCOS, P-value, GCS, Patient, Cash, Șaeș, Spruce, Outline, CAH, Clinical trial, Safety, Hyperandrogenism, Polycystic ovary syndrome, ULN, Research and development, Food, FDA, Pharmaceutical industry

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2023 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2023 and provided corporate updates.
  • “We are grateful to all the patients, families, study team and investigators who supported the CAHmelia-203 clinical trial,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, Spruce Biosciences.
  • Non-cash stock-based compensation expense for the year ended December 31, 2023 was $4.6 million compared to $3.6 million in 2022.
  • Net Loss: Net loss for the year ended December 31, 2023 was $47.9 million compared to $46.2 million in 2022.

Spruce Power to Release Fourth Quarter and Full-Year 2023 Results and Host Conference Call on March 14

Retrieved on: 
Wednesday, February 28, 2024
Technology, Environment, Batteries, Alternative Energy, Green Technology, Energy, Webcast, Spruce

Spruce Power Holding Corporation (NYSE: SPRU) (“Spruce”), a leading owner and operator of distributed solar energy assets across the United States, today announced that it will report fourth quarter and full-year 2023 financial results after the stock market close on Thursday, March 14, 2024.

Key Points: 
  • Spruce Power Holding Corporation (NYSE: SPRU) (“Spruce”), a leading owner and operator of distributed solar energy assets across the United States, today announced that it will report fourth quarter and full-year 2023 financial results after the stock market close on Thursday, March 14, 2024.
  • Spruce will issue a press release reporting its results, which will be available on the Investor Relations section of its website at https://investors.sprucepower.com/overview/default.aspx .
  • Management will then host a conference call and webcast for investors and analysts at 2:30 P.M. MDT to discuss the results.
  • A replay of the conference call can be accessed by dialing 800-770-2030 and referencing conference ID 6052195.

Spruce & Gander Traveling Down Under with Street Furniture Australia Keeping Sustainability in Sight

Retrieved on: 
Thursday, February 8, 2024
Architecture, SAN, Marketing, Gander, Innovation, Spruce, Culminating project, Longevity

SAN MARCOS, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Spruce & Gander is embarking on a sustainability journey to Sydney, Australia this March. This trip holds particular significance in highlighting the importance of sustainability through the products and practices of Spruce & Gander’s manufacturing partner, Street Furniture Australia. Along for the journey will be two winners of Spruce & Gander’s Rapid Ideation Game, who have won a landscape architecture-focused vacation to Sydney, Australia.

Key Points: 
  • SAN MARCOS, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Spruce & Gander is embarking on a sustainability journey to Sydney, Australia this March.
  • This trip holds particular significance in highlighting the importance of sustainability through the products and practices of Spruce & Gander’s manufacturing partner, Street Furniture Australia.
  • “Good design is inherently sustainable," remarked June Lee Boxsell, Head of Marketing and Innovation at Street Furniture Australia.
  • The collaboration between Street Furniture Australia and Spruce & Gander underscores the shared commitment to a sustainable future.